PENNINGTON, N.J.--(BUSINESS WIRE)--BioLeap, Inc. today announced the re-location of its headquarter offices and the expansion of its research staff to accommodate the continued successful growth of the company.
Effective today, BioLeap has moved its corporate offices to Pennington, NJ, from Ewing, NJ. Additionally, the company is expanding its research center in Chapel Hill, NC and its software development team in Boston, MA.
David Pompliano, Ph.D., chief executive officer of BioLeap, commented:
“These actions reflect the growing demand we have found for our proprietary services in molecular design, demand from not only the prescription-pharmaceutical industry but also companies focused on health-related consumer products and agrochemicals.
“In addition to this work with our clients, we are advancing our own pharmaceutical pipeline of unique molecular designs fashioned for biological targets that have proved refractory to traditional drug-discovery methods.
“We expect our staffing needs will expand further with continued corporate success.”
Following earlier agreements with pharmaceutical companies, BioLeap this year announced research alliances with Unilever in consumer products and with Syngenta in crop-protection products. Recently the company also appointed a sales executive in a further step in the commercialization of its molecular-design capabilities.
BioLeap chemists have made proprietary advances in creating and using computer simulations both to design compounds de novo, chemical fragment by chemical fragment, and to tailor existing compound designs. Every BioLeap design builds on calculations of the binding energies between the compound being fashioned in silico and its biological target.
The exactitude of this method seeks to ensure greater affinity for the target than is available through conventional compound screening and to achieve other optimal chemical properties. The method thus promises to reduce costly and time-consuming trial and error, minimizing the number of compounds that need actually to be synthesized and then tested, improving the odds of success in early research, and accelerating overall product development.
The new BioLeap headquarters address, effective today, is 238 West Delaware Avenue, Pennington, NJ 08534.
About BioLeap
BioLeap is a pioneer in computational fragment-based molecular design. In pharmaceutical applications, the company uses its proprietary software to design drug candidates both through its internal programs and in collaboration with partners. BioLeap thus addresses one of the biggest problems in drug discovery: the limitation of drug-like and patentable leads for important but often difficult biological targets. This in silico design capability also finds application in product development for the consumer-product and agriculture industries, promising to achieve greater speed, economy, and odds of success than traditional compound screening. More information is available at www.bioleap.com. On the home page, a video offers an overview of the company by CEO David Pompliano.